Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.

Pier Luigi ZinzaniRobert ChenPhilippe ArmandNathalie A JohnsonPauline BriceJohn RadfordVincent RibragDaniel MolinTheodoros P VassilakopoulosAkihiro TomitaBastian von TresckowMargaret A ShippJianxin LinAkash NaharArun BalakumaranCraig H Moskowitz

Published in: Leukemia & lymphoma (2020)

Keyphrases

hodgkin lymphoma
stem cell transplantation
high dose
cell therapy
low dose
open label
randomized controlled trial
clinical trial
mesenchymal stem cells
acute myeloid leukemia
data analysis
epidermal growth factor receptor